Immunomodulator loaded microneedle arrays for targeted intradermal drug delivery to skin tumors

Topical therapy with imiquimod in a cream [5% w/w imiquimod cream (Aldara™)] for the treatment of nodular basal cell carcinoma (BCC) currently results in low cure rates, attributed to low imiquimod permeation. Herein we have developed novel microneedle array patches (MAPs), to maximize imiquimod int...

Full description

Saved in:
Bibliographic Details
Main Authors: Akmal H. Sabri, Fiona Smith, Zachary Cater, Pratik Gurnani, Ami Nash, Victoria Brentville, Lindy Durrant, John McKenna, Joel Segal, David J. Scurr, Maria Marlow
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Drug Delivery
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/10717544.2025.2527824
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849320350415847424
author Akmal H. Sabri
Fiona Smith
Zachary Cater
Pratik Gurnani
Ami Nash
Victoria Brentville
Lindy Durrant
John McKenna
Joel Segal
David J. Scurr
Maria Marlow
author_facet Akmal H. Sabri
Fiona Smith
Zachary Cater
Pratik Gurnani
Ami Nash
Victoria Brentville
Lindy Durrant
John McKenna
Joel Segal
David J. Scurr
Maria Marlow
author_sort Akmal H. Sabri
collection DOAJ
description Topical therapy with imiquimod in a cream [5% w/w imiquimod cream (Aldara™)] for the treatment of nodular basal cell carcinoma (BCC) currently results in low cure rates, attributed to low imiquimod permeation. Herein we have developed novel microneedle array patches (MAPs), to maximize imiquimod intradermal delivery and retention in the skin, with potential as an efficacious treatment for BCC. Enhanced delivery of imiquimod in pig skin and ex vivo BCC tissue was found with the obelisk poly N-acryloylmorpholine (pNAM) MAPs as compared to the 5% w/w imiquimod cream and MAPS manufactured from a commercially available polymer (PVPVA). Additionally, the increased retention in ex vivo BCC tissue was found with the obelisk pNAM MAPs as compared to the 5% w/w imiquimod cream. In addition, detailed characterization of single needles and mechanistic studies of MAPs in tissue using mass spectrometry imaging confirmed the imiquimod homogeneity in the needles. Most importantly, the in vivo tumor efficacy study showed that pNAM obelisk MAPs could deliver imiquimod into the tumor, retarding tumor growth. This study suggests that the drug loaded obelisk pNAM MAPs manufactured here may be of clinical utility for localized intradermal delivery of imiquimod.
format Article
id doaj-art-7d4c746cdc874739bfac9384b98cd74b
institution Kabale University
issn 1071-7544
1521-0464
language English
publishDate 2025-12-01
publisher Taylor & Francis Group
record_format Article
series Drug Delivery
spelling doaj-art-7d4c746cdc874739bfac9384b98cd74b2025-08-20T03:50:07ZengTaylor & Francis GroupDrug Delivery1071-75441521-04642025-12-0132110.1080/10717544.2025.2527824Immunomodulator loaded microneedle arrays for targeted intradermal drug delivery to skin tumorsAkmal H. Sabri0Fiona Smith1Zachary Cater2Pratik Gurnani3Ami Nash4Victoria Brentville5Lindy Durrant6John McKenna7Joel Segal8David J. Scurr9Maria Marlow10School of Pharmacy, University of Nottingham, Nottingham, UKSchool of Pharmacy, University of Nottingham, Nottingham, UKAdvanced Manufacturing Technology Research Group, Faculty of Engineering, University of Nottingham, Nottingham, UKSchool of Pharmacy, University of Nottingham, Nottingham, UKSchool of Pharmacy, University of Nottingham, Nottingham, UKScancell Ltd, University of Nottingham Biodiscovery Institute, Nottingham, UKScancell Ltd, University of Nottingham Biodiscovery Institute, Nottingham, UKLeicester Royal Infirmary University Hospitals Leicester Dermatology Department, Infirmary Square, Leicester, UKAdvanced Manufacturing Technology Research Group, Faculty of Engineering, University of Nottingham, Nottingham, UKSchool of Pharmacy, University of Nottingham, Nottingham, UKSchool of Pharmacy, University of Nottingham, Nottingham, UKTopical therapy with imiquimod in a cream [5% w/w imiquimod cream (Aldara™)] for the treatment of nodular basal cell carcinoma (BCC) currently results in low cure rates, attributed to low imiquimod permeation. Herein we have developed novel microneedle array patches (MAPs), to maximize imiquimod intradermal delivery and retention in the skin, with potential as an efficacious treatment for BCC. Enhanced delivery of imiquimod in pig skin and ex vivo BCC tissue was found with the obelisk poly N-acryloylmorpholine (pNAM) MAPs as compared to the 5% w/w imiquimod cream and MAPS manufactured from a commercially available polymer (PVPVA). Additionally, the increased retention in ex vivo BCC tissue was found with the obelisk pNAM MAPs as compared to the 5% w/w imiquimod cream. In addition, detailed characterization of single needles and mechanistic studies of MAPs in tissue using mass spectrometry imaging confirmed the imiquimod homogeneity in the needles. Most importantly, the in vivo tumor efficacy study showed that pNAM obelisk MAPs could deliver imiquimod into the tumor, retarding tumor growth. This study suggests that the drug loaded obelisk pNAM MAPs manufactured here may be of clinical utility for localized intradermal delivery of imiquimod.https://www.tandfonline.com/doi/10.1080/10717544.2025.2527824Microneedlesbasal cell carcinomaimiquimodmass spectrometryskin permeationToF-SIMS
spellingShingle Akmal H. Sabri
Fiona Smith
Zachary Cater
Pratik Gurnani
Ami Nash
Victoria Brentville
Lindy Durrant
John McKenna
Joel Segal
David J. Scurr
Maria Marlow
Immunomodulator loaded microneedle arrays for targeted intradermal drug delivery to skin tumors
Drug Delivery
Microneedles
basal cell carcinoma
imiquimod
mass spectrometry
skin permeation
ToF-SIMS
title Immunomodulator loaded microneedle arrays for targeted intradermal drug delivery to skin tumors
title_full Immunomodulator loaded microneedle arrays for targeted intradermal drug delivery to skin tumors
title_fullStr Immunomodulator loaded microneedle arrays for targeted intradermal drug delivery to skin tumors
title_full_unstemmed Immunomodulator loaded microneedle arrays for targeted intradermal drug delivery to skin tumors
title_short Immunomodulator loaded microneedle arrays for targeted intradermal drug delivery to skin tumors
title_sort immunomodulator loaded microneedle arrays for targeted intradermal drug delivery to skin tumors
topic Microneedles
basal cell carcinoma
imiquimod
mass spectrometry
skin permeation
ToF-SIMS
url https://www.tandfonline.com/doi/10.1080/10717544.2025.2527824
work_keys_str_mv AT akmalhsabri immunomodulatorloadedmicroneedlearraysfortargetedintradermaldrugdeliverytoskintumors
AT fionasmith immunomodulatorloadedmicroneedlearraysfortargetedintradermaldrugdeliverytoskintumors
AT zacharycater immunomodulatorloadedmicroneedlearraysfortargetedintradermaldrugdeliverytoskintumors
AT pratikgurnani immunomodulatorloadedmicroneedlearraysfortargetedintradermaldrugdeliverytoskintumors
AT aminash immunomodulatorloadedmicroneedlearraysfortargetedintradermaldrugdeliverytoskintumors
AT victoriabrentville immunomodulatorloadedmicroneedlearraysfortargetedintradermaldrugdeliverytoskintumors
AT lindydurrant immunomodulatorloadedmicroneedlearraysfortargetedintradermaldrugdeliverytoskintumors
AT johnmckenna immunomodulatorloadedmicroneedlearraysfortargetedintradermaldrugdeliverytoskintumors
AT joelsegal immunomodulatorloadedmicroneedlearraysfortargetedintradermaldrugdeliverytoskintumors
AT davidjscurr immunomodulatorloadedmicroneedlearraysfortargetedintradermaldrugdeliverytoskintumors
AT mariamarlow immunomodulatorloadedmicroneedlearraysfortargetedintradermaldrugdeliverytoskintumors